Diurnal Group Live Discussion

bernstein.babe 21 Feb 2020

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Major breakot about to start could drive sp toward 100p+ as we move closer to the drug approvals likely before year end . [link]

bernstein.babe 13 Feb 2020

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP GREAT News out today …NDA accepted by FDA and the Drug could be approved in Q3 … Still the CHEAPEST and most attractive small cap Biotech in UK . A potential 10 Bagger here Diurnal : US FDA Accepts NDA Application for Alkindi marketscreener.com Diurnal : US FDA Accepts NDA Application for Alkindi | MarketScreener Regulatory Story Go to market news section ... | February 13, 2020 Application seeks approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents NDA could potentially be approved in Q3 2020 Diurnal (DNL) Market Cap £23 M Price: 28p New Presentation [link]

bernstein.babe 08 Jan 2020

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP The most underpriced and attractive british biotech company with MASSIVE upside potential .Still think this sleeping giant has 10+ bagger upside potential and 2020 could be the year for DNL with all the approvals and partnerships expected during the year .GL Diurnal (DNL) Market Cap £24 M Price: 29p DCF valuation of 202p per share hardmanandco.com DNL-2019-results-5-November-2019.pdf 737.69 KB Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses Presentation diurnal.co.uk full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf 1803.52 KB Upcoming Catalysts: US-NDA acceptance for Alkindi in Februry 2020 MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 1Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 $88m market opportunity (Europe and US) for Paediatric AI (inc CAH) $351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia $2,767m market opportunity (Europe and US) for Adrenal Insufficiency Ceo bought another 25k shares at 30p [link]

bernstein.babe 16 Dec 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP GREAT NEWS OUT Market cap £25 million Chronocort MAA Submitted in Europe [link] Significant opportunity to address unmet patient need, in a market estimated at $250 million Marketing authorisation anticipated in Q1 2021

bernstein.babe 20 Nov 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Diurnal (DNL) Price:30p --Market Cap £26 M --Cash £9 M–MEGA milestones expected within 4 weeks = 300-500% GEM Approaching anumber of near-term milestones…5 November 2019 hardmanandco.com DNL-2019-results-5-November-2019.pdf 737.69 KB Valuation -DCF 202p per share The consequence of the Chronocort trial outcome is minimal in the bigger picture, as it has delayed both the EMA MAA submission and the start of the US Phase III trial only by about six months. Hence, there has not been a material change to our DCF valuation based on our clearly-stated assumptions in ourresearch note, published on 25 April 2019. The net present value of the cashflows that could be generated from DNL’s first two products equates to £305m. Risk-adjustment to take account of the different stages of development in different territories reduces this to £171m, or 202p per share. DITEST™(Hypogonadism) study readout Q4 2019 **Alkindi® US NDA submission to the FDA(paediatric AI,including CAH)Q4 2019 ** **Chronocort® European regulatory submission to the EMA(CAH)Q4 2019 ** Conclude US partnering discussions for Alkindi®(Chronocort®)H1 2020 Presentation diurnal.co.uk full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf 1803.52 KB

bernstein.babe 08 Aug 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP looks like consolidation is over , with good news this ultra low float stock will hit 100p very fast and there are many big milestones on the way … Upcoming Milestones Alkindi launch in additional EU States during 2H 2019 US-NDA submission for Alkindi in Q4 2019 MAA submission for Chronocort approval in Q4 2019 Alkindi approval in Israel expected in 1H 2020 Alkindi approval in Australia expected in 1H 2020 US-Partner Deal for Alkindi could happen anytime now US-Partner Deal for Chronocort could happen anytime now Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now “Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.

bernstein.babe 07 Aug 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Some Insider buying by Ceo today and further Alkindi launches see reply from IR below Dear Mr xxxxxxxx, Alkindi launched in Sweden and Denmark in early July with our partner, Frost Pharma (formerly Anthrop). We had a small delay to our original timelines due to delays arising from our Brexit arrangements, and the introduction of the Falsified Medicines Directive which required to changes to the Alkindi packaging. Best regards Richard

bernstein.babe 05 Aug 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP i send an email to the company asking if they are still on track for NDA and MAA submission of their drugs and about potential partnerships ,below is the answer from CFO of Diurnal . Dear Mr XXXXXXXX, I can answer your questions as far as the information is already in the public domain. I can confirm the Alkindi NDA submission and Chronocort MAA submission remain on track for Q4 2019. We have disclosed to the market that we are in US licensing discussions. We have not put a timeline on a deal, other than to comment that we would like to have a commercial partner in place for Alkindi around the time of the NDA submission – so it is possible we could see partnerships before the end of 2019. We share your frustrations regarding the share price but do expect it to remain volatile until we get closer to potential approvals in the US and Europe. As I mentioned before, we have a very active investor relations programme, and do announce all significant newsflow as it happens. Best regards Richard Bungay

bernstein.babe 02 Aug 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP great buying opportunity on this ugly stock market day

bernstein.babe 01 Aug 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP some washout ongoing on small volume after 80% jump in short time …Any dip is a mega buying opp here market cap of 39 million is still a gift and lots of big news coming (see above) to push this low float rocket much higher .GL

Ripley94 31 Jul 2019

G .. last day of july 2019 DNL… XXXX This was 27p on 15 July 2019 . Now 45p it has nearly doubled . ( And again to 100p !!!)

bernstein.babe 29 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Shareholders here should put a high gtc sell order in like 100p ,so your shares will not available for shorts and more important it reduces the free shares on market so it helps the stock to make even much bigger jumps on good news . Thank you guys How to Prevent your Shares Holdings from being Shorted [link] Q:What can you do to prevent your shares holdings from being shorted? A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account. There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps . Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on. In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.

bernstein.babe 29 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP and the ralllyyyyyyyy continues , stock still brutally undervalued at 38 million and the best still to come which could push this undiscovered stock even faster to the upside .LOVE IT Upcoming Milestones Alkindi launch in additional EU States during 2H 2019 US-NDA submission for Alkindi in Q4 2019 EMA submission for Chronocort approval in Q4 2019 US-Partner Deal for Alkindi could happen anytime now US-Partner Deal for Chronocort could happen anytime now Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.

bernstein.babe 26 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Partnerdeal news could hit the wire anytime now which means upfront payments to DNL such news could push this low float stock between 50-100% . “Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.”

bernstein.babe 25 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP next FUM here which i bought at 7p and sold at 45p to buy more of this undiscovered goldmine .DNL has minimum 500% upside potential from current price .GL